SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending amid a flurry of analyst upgrades raising price targets, yet concurrently faces widespread community discussion regarding a rumored short-seller report and persistent allegations of extreme overvaluation. This dynamic fuels significant speculative interest, with traders actively debating its fundamental health against a backdrop of frequently volatile price movements and accusations of market manipulation.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is experiencing intense trending activity driven by recently reported strengthened financials from warrant exercises and an AI licensing partnership in Africa. The stock's rapid ascent has ignited widespread discussion among the community, fueling speculation of a massive short squeeze due to its low float and high cost to borrow, despite some expressing concerns over valuation.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is a focal point of market discussion, driven by escalating industrial demand for AI and EV technologies, alongside tightening global supply from export restrictions. Traders are actively debating an ongoing "silver squeeze," with aggressive bulls anticipating further significant appreciation while bears caution against a speculative bubble.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently trending after securing a contract with the U.S. Air Force Research Laboratory to advance multi-domain swarming capabilities with its SwarmOS platform, extending its autonomous systems integration to satellites. This news has sparked significant community debate, with many investors anticipating substantial growth within the defense AI and robotics sector and discussing a potential short squeeze, while others remain cautious due to the undisclosed contract value and past stock volatility.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amidst reports of potential merger talks with Automation Anywhere, sparking significant community debate regarding a possible short squeeze given the stock's high short interest. Many are viewing this, along with recent government contract wins, as a pivotal moment for the enterprise AI provider, while others remain cautious about the long-term implications.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is surging to new all-time highs, driven by substantial institutional options activity and growing apprehension over dollar weakness and geopolitical tensions. Community discussions are sharply polarized between those anticipating further parabolic gains as a hedge against fiat currency debasement and others cautioning a speculative 'mania' ripe for a sharp correction.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is experiencing significant investor attention following its latest earnings, where shares surged after reporting positive U.S. same-store sales and transaction growth for the first time in two years, signaling traction for its 'Back to Starbucks' strategy. While the community is debating whether this renewed customer traffic can overcome persistent margin pressures from higher costs, many are watching if this momentum can translate into sustained profitable growth amidst rising competition.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is a key trending stock following record orders and an optimistic revenue outlook for 2026 and beyond, fueled by the accelerating AI boom driving demand for its critical chipmaking equipment. The community is actively discussing the company's indispensable role in advanced chip manufacturing and its new share buyback program, though some express caution regarding its high valuation and recent price volatility.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is experiencing significant selling pressure after a proposed near-flat Medicare Advantage payment rate for 2027 from the Trump administration, falling short of market expectations. This development has triggered a polarized community discussion, with some investors seizing the opportunity to "buy the dip" amid expectations of a rebound, while others express deep concern over the long-term profitability and viability of the managed care business model. The community is actively debating whether this is a political negotiation tactic or a fundamental challenge impacting Humana and its peers in the healthcare sector.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is a top trending stock following substantial new contracts for its fuel cell technology and positive analyst coverage, all driven by the escalating power demands of AI data centers and broader grid infrastructure needs. The community is actively discussing the company's rapid growth and its crucial role in providing immediate, on-site energy solutions. Despite some valuation concerns, many anticipate continued revenue expansion and further strategic announcements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$OSTX What is the expected impact on PPS when the filing of the BLA is announced?

JTstockwatch

Corey Workman

StockTwits Web

OS Therapies Inc

 What is the expected impact on PPS when the filing of the BLA is announced?

@NoFooling It’s a de-risking step so potentially could see upward movement but keep in mind there is still no income and the approval isn’t likely until Q3. Could boost confidence and get more jumping on board to ride the potential rocket but I wouldn’t hold my breath until we get closer to approval. For now enjoy a great in price and accumulate as much as you can justify for the risk. The upside potential is huge but patience is a virtue.

The Wolf of Finland

peter het

StockTwits for iOS

 It’s a de-risking step so potentially could see upward movement but keep in mind there is still no income and the approval isn’t likely until Q3. Could boost confidence and get more jumping on board to ride the potential rocket but I wouldn’t hold my breath until we get closer to approval. For now enjoy a great in price and accumulate as much as you can justify for the risk. The upside potential is huge but patience is a virtue.

Fenderdork

@NoFooling BLA filing confirmation could trigger a 20-50% upside in the immediate term.$1.76-$2.20

Post-MHRA and EMA submissions (February-March 2026), expect modest additional gains of 10-30%. $2.00-$2.50

U.K. approval in Q2 could catalyze a stronger rally, estimating 30-60% upside from pre-approval levels. $2.50-$3.50

Wall Street&#39;s 12-month consensus targets are significantly higher at $11.49-$18.50 (Strong Buy rating), implying over 700-1,200% longer-term upside on successful approvals and commercialization.

 BLA filing confirmation could trigger a 20-50% upside in the immediate term.$1.76-$2.20

Post-MHRA and EMA submissions (February-March 2026), expect modest additional gains of 10-30%. $2.00-$2.50

U.K. approval in Q2 could catalyze a stronger rally, estimating 30-60% upside from pre-approval levels. $2.50-$3.50

Wall Street's 12-month consensus targets are significantly higher at $11.49-$18.50 (Strong Buy rating), implying over 700-1,200% longer-term upside on successful approvals and commercialization.

@Fenderdork Thanks. Based on OSTX PR it seems the management expects the PPS&gt;$9 to incentives Warrant Exercise. What catalysts are on the horizon that might facilitate a PPS&gt;$9?

 Thanks. Based on OSTX PR it seems the management expects the PPS>$9 to incentives Warrant Exercise. What catalysts are on the horizon that might facilitate a PPS>$9?

@JTstockwatch Thanks for your prospective.

@NoFooling BLA submission is the big one. Beyond that I couldn’t tell you what would make this move. Good PR hasn’t moved this price basically at all since I’ve been in about a year ago or more. In fact at times it’s even dropped. Until there is a real indicator of cash income possible like PRV voucher, FDA or overseas approval, etc. I wouldn’t be overly confident in seeing a ton of movement.  There’s also the promise of shares of their new Animal Health spinoff which holds a deadline of current share ownership to take advantage of. Will that move the needle? I don’t know. 🤷 The good news is HER-2 looks promising and that’s what we’re banking on right now.  Let’s let that BLA filing go through in a few days and see if that stirs up any action. It might but it might not. Patience.

Raimundas Veitas

 BLA submission is the big one. Beyond that I couldn’t tell you what would make this move. Good PR hasn’t moved this price basically at all since I’ve been in about a year ago or more. In fact at times it’s even dropped. Until there is a real indicator of cash income possible like PRV voucher, FDA or overseas approval, etc. I wouldn’t be overly confident in seeing a ton of movement.  There’s also the promise of shares of their new Animal Health spinoff which holds a deadline of current share ownership to take advantage of. Will that move the needle? I don’t know. 🤷 The good news is HER-2 looks promising and that’s what we’re banking on right now.  Let’s let that BLA filing go through in a few days and see if that stirs up any action. It might but it might not. Patience.

@NoFooling it takes 60 days for the FDA to review the filing and accept it as it is or ask for more data etc. After 2 months the share price will climb to the PDUFA date in early autumn, most likely September.

 it takes 60 days for the FDA to review the filing and accept it as it is or ask for more data etc. After 2 months the share price will climb to the PDUFA date in early autumn, most likely September.